Axinn Advised Thermo Fisher on $12.5B Acquisition of QIAGEN
March 3, 2020

Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed $12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander, who were assisted by Varnitha Siva.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.